Table 1.

Pretreatment characteristics of white and black AML patients [numbers (%)]

		White N=399	Black N=105	p-value
Age	Median (years)	61	54	<0.001
Sex	Male	211 (53%)	47 (45%)	<0.001
	Female	188 (47%)	58 (55%)
Onset	de novo	278 (70%)	76 (72%)	0.11
	Secondary	114 (29%)	25 (24%)	0.20
	AHD	74 (19%)	13 (12%)	0.11
	t-AML	40 (10%)	12 (11%)	0.47
Karyotype	t(15;17)	24 (6%)	9 (9%)	0.15
	Other favorable	23 (6%)	9 (9%)	0.31
	t(8;21)	7 (2%)	5 (5%)	0.08
	inv(16), t(16;16)	16 (4%)	4 (4%)	0.91
	Intermediate	210 (53%)	41 (39%)	0.02
	Normal	167 (42%)	28 (27%)	0.02
	Unfavorable	113 (29%)	38 (36%)	0.17
	Complex	49 (12%)	27 (26%)	0.001
	Missing	29 (7%)	9 (8%)	0.54
FLT3*	Wild-type	45	6	0.58
	ITD	27	6	0.54
	D835	5	1	0.88
	Missing	138	13	0.75

^*intermediate-risk karyotypes

AHD = antecedent hematologic disorder

t-AML= therapy-related AML

ITD= internal tandem duplication